Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920969 | 0.91 | GRM2 (0.37) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6921833 | 0.87 | RAB9A (0.42) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6922247 | 0.87 | KMT2A (0.40) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6920907 | 0.86 | GRM5 (0.40) | RAB9ANPC1L3MBTL1 | |
| SCHEMBL6922263 | 0.85 | MAP4K4 (0.42) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6920741 | 0.84 | RAB9A (0.41) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6921830 | 0.82 | RAB9A (0.41) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6920796 | 0.82 | SSTR2 (0.45) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6920820 | 0.82 | RAB9A (0.43) | RAB9ANPC1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL6921785 | 0.82 | PIM1 (0.38) | L3MBTL1CYP1A2CYP3A4BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | RAB9A 1387/4885NPC1 811/4885L3MBTL1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.